This work is licensed under a Creative Commons Attribution 4.0 International License.
Sequence 21 from Patent US 20110319336
General Information
DRACP ID DRACP01402
Peptide Name Sequence 21 from Patent US 20110319336
Sequence YHWYGYTPQNVIGGGGGRLLRRLLRRLLRK
Sequence Length 30
UniProt ID Not available
PubChem CID Not available
Origin Synthetic construct
Type Synthetic peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Not available
Disulfide/Other Bond Not available
N-terminal Modification Not available
C-terminal Modification Not available
Other Modification None
Chiral L
Physicochemical Information
Formula C163H262N54O37
Absent amino acids ACDEFMS
Common amino acids GLR
Mass 408766
Pl 12.22
Basic residues 8
Acidic residues 0
Hydrophobic residues 9
Net charge 8
Boman Index -6845
Hydrophobicity -63.67
Aliphatic Index 100.67
Half Life
Mammalian: 2.8 hour
Yeast: 10 min
E.coli: 2 min
Extinction Coefficient cystines 9970
Absorbance 280nm 343.79
Polar residues 11
Amino acid distribution
Literature Information
Literature 1
Pubmed ID Not available
Title Not available
Doi Not available
Year Not available
Patent
Patent ID US 2011/0319336 A1
Patent Title Selective anticancer chimeric peptide.
Other Iinformation Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013
Other Published ID CN102238965A EP2370107A2 WO2010064207A2 WO2010064207A3
This work is licensed under a Creative Commons Attribution 4.0 International License.